FDA to Let Caronia Stand; Agency Will Factor Ruling Into Guidance Development

Drug Industry Daily
A A
The FDA will not seek further review of the 2nd Circuit’s decision in U.S. v. Caronia as the agency doesn’t view the decision as a significant threat to its misbranding enforcement drive.

To View This Article:

Login

Subscribe To Drug Industry Daily